Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (109)

I-002Seef Abdalla

Pharmacokinetics of Cefotaxime and its metabolite Desacetyl-cefotaxime to optimize dosing in critically ill children and children with Sickle Cell Disease.

Wednesday 10:30-12:00

I-003Oliver Ackaert

Exposure–Response Analyses of Erdafitinib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Wednesday 10:30-12:00

I-004Arkadiusz Adamiszak

Do critically ill patients undergoing continuous renal replacement therapy require levofloxacin dosage adjustments? Levofloxacin PopPK model and dosage simulations based on retrospective data and developed using open-source R packages.

Wednesday 10:30-12:00

I-005Wouter Ahmed

Development of a mechanistic joint model describing multivariate continuous and event outcomes linked through a latent variable

Wednesday 10:30-12:00

I-006Ludovica Aiello

Quantitative evaluation of RC-106 antitumor activity in GBM spheroids through tumor growth inhibition modeling based on cell counts data

Wednesday 10:30-12:00

I-007Arwa Alghaith

Application of a population pharmacokinetic model of olaparib in patients with recurrent glioblastoma and non-small cell lung cancer

Wednesday 10:30-12:00

I-008Engi Algharably

Population Pharmacokinetics of Busulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

Wednesday 10:30-12:00

I-010Muyesaier Alifu

A Population-based Time-to-Event Model for Pregnancy Loss Risk Prediction in frozen-thawed embryo transfer (FET)

Wednesday 10:30-12:00

I-011Nikolaos Alimpertis

The Finite Absorption Time (F.A.T.) Concept: A new Model Informed Drug Development (MIDD) world is emerging in all phases of drug and generics development

Wednesday 10:30-12:00

I-012Guiva Annane

ß-lactams Antibiotics in Obese Adults: A Review of Population Pharmacokinetic Analyses

Wednesday 10:30-12:00

I-013Richard Anziano

Predictive Probability of Success (PPOS) in Longitudinal Endpoint to Predict Trial Outcome: What can we learn from a retrospective interim analysis?

Wednesday 10:30-12:00

I-014Ahmed Ibrahim Abdelaziz Atta

Quantitative Modeling of Radiation-Induced Immune Response in Normal Lung Tissue

Wednesday 10:30-12:00

I-015Flavie Audy

Modeling Targeted Radionuclide Therapy: General Approach to Optimize Dose Selection

Wednesday 10:30-12:00

I-016Kay Hoong Chow

Quantifying natural amyloid plaque accumulation using ADNI, BIOFINDER, A4 and LEARN datasets

Wednesday 10:30-12:00

I-017Sally Babiker

Characterising the effect of sex differences in the exposure and safety profile of anticancer chemotherapies

Wednesday 10:30-12:00

I-018Idris Bachali Losada

Towards precision modeling for accurate tumour growthprediction leveraging multiple modalities

Wednesday 10:30-12:00

I-020Salma Bahnasawy

Modelling antibiotic PKPD in a lung-mimicking transwell model

Wednesday 10:30-12:00

I-021Vanessa Baier

A PB-QSP module for ocular applications for the Open Systems Pharmacology – A vancomycin example

Wednesday 10:30-12:00

I-022Anastasiia Bakhmach

A benchmark of machine learning feature selection methods for stable identification of biomarkers of resistance to immunotherapy in lung cancer

Wednesday 10:30-12:00

I-023Pavel Balazki

Predicting Hormonal Contraceptives Drug-Drug-Interactions by leveraging the model database of the Open Systems Pharmacology

Wednesday 10:30-12:00

I-024Asma Baliouze

Population Pharmacokinetic and Exposure-Response Modeling of Mavacamten in Hypertrophic Cardiomyopathy: Impact of Japanese Ethnicity.

Wednesday 10:30-12:00

I-025Pauline Bambury

Exploration of optimal monoclonal antibody properties using a target-mediated drug disposition framework and the InSilicoTrials’ platform for study design simulations

Wednesday 10:30-12:00

I-026Luca Barberi

Replacing transit compartments with the analytical solution of a partial differential equation in malaria liver-stage modeling

Wednesday 10:30-12:00

I-027Imke Bartelink

Comparative Evaluation Of Pharmacokinetic Models For Total And Unbound Drug Concentrations: What Is The Consensus For Modelling Nonlinear Protein Binding?

Wednesday 10:30-12:00

I-028Paul Baverel

A minimal physiologically-based pharmacokinetic/pharmacodynamic mouse xenograft model to inform the evaluation of 212Pb-based Radio-DARPins targeting DLL3

Wednesday 10:30-12:00

I-029Tassadit Belabbas

A semi-mechanistic pharmacokinetic-pharmacodynamic model to characterize thrombocytopenia in patients with biliary tract cancer, and advanced or metastatic solid tumors for a selective antagonist of MDM2-p53 interaction

Wednesday 10:30-12:00

I-030Massinissa Beldjenna

Beyond averages: Why capturing cellular variability matters in viral dynamic modeling.

Wednesday 10:30-12:00

I-031Stella Belin

The Challenges of Reproducible Computations in Pharmacometrics: Best Practices and Solutions

Wednesday 10:30-12:00

I-033Daniel Bending

Integrating Clinical Utility Index in Early Phase Oncology Trials: A Case Study with Antibody-Drug Conjugates

Wednesday 10:30-12:00

I-034Racym Berrah

Impact of Residual Error Handling on Model Informed Precision Dosing and AUC Calculation: A Case Study with Tacrolimus

Wednesday 10:30-12:00

I-035Stéphane Bertin

Population pharmacokinetics of levosimendan and its metabolites OR-1855 and OR-1896 in critically ill adults and children on ECMO

Wednesday 10:30-12:00

I-036Lisanne Bevers

A pooled population PK analysis investigating once-daily standard dosing of DTG in HIV/TB co-infected children weighing 3 kg or more.

Wednesday 10:30-12:00

I-037Robert Bies

Multi-Objective Optimization for Population Pharmacokinetic Model Selection: Evaluating NSGA-III Performance

Wednesday 10:30-12:00

I-038Davide Bindellini

Comparison of immediate- and modified-release hydrocortisone to achieve therapeutic goals in congenital adrenal hyperplasia

Wednesday 10:30-12:00

I-039Laura Boles

A translational PKPD framework for the prediction of the early bactericidal activity of telacebec for the treatment of pulmonary tuberculosis.

Wednesday 10:30-12:00

I-042Sieto Bosgra

Antibody pairs inducing selective clustering on cells co-expressing two antigens – a HexElect QSP model

Wednesday 10:30-12:00

I-043Salim Bouchene

Population pharmacokinetic analysis of doxecitine and doxribtimine in patients with thymidine kinase 2 deficiency and in healthy volunteers

Wednesday 10:30-12:00

I-044Dominic Bräm

pmxNODE: A novel R-package to make low-dimensional NODEs available in Monolix, NONMEM, and nlmixr2

Wednesday 10:30-12:00

I-045Andrew Brandon

Population pharmacokinetics of mitoxantrone in children with cancer

Wednesday 10:30-12:00

I-046Myriam Briki

Population Pharmacokinetics of Intravenous Methotrexate: A Model-Based Meta-Analysis Integrating Individual Patient Data from Three Independent Studies

Wednesday 10:30-12:00

I-047Nils Bundgaard

Longitudinal Biomarker Modeling of T2D-Patients Treated With Semaglutide

Wednesday 10:30-12:00

I-048Chloé Burlot

Assessment of S65487 PK differences from therapeutic doses to microdose: exploring linear and nonlinear processes

Wednesday 10:30-12:00

I-049Jose Miguel Calderin Miranda

Semi-mechanistic population pharmacokinetic modelling of the novel antituberculosis drug TBAJ-876 and its metabolite M3 in healthy volunteers

Wednesday 10:30-12:00

I-050Elio Campanile

An enhanced PBPK model for predicting mRNA-encoded therapeutic trafficking in mice

Wednesday 10:30-12:00

I-051Kangna CAO

Predicting tissue iron distribution following intravenous ferric carboxymaltose therapy using a physiologically-based pharmacokinetic model

Wednesday 10:30-12:00

I-052Letizia Carrara

Characterization of the Drug–Drug Interaction potential of vorasidenib via PBPK modelling

Wednesday 10:30-12:00

I-053Adriana Castiñeiras

Population analysis of the clinical pharmacokinetic characteristics of a letrozole long-acting injectable formulation

Wednesday 10:30-12:00

I-054Geraldine Celliere

mlxDesignEval: A novel R package for design evaluation based on MonolixSuite, and its comparison to popED and PFIM

Wednesday 10:30-12:00

I-055James Chun Yip Chan

Integration of Physics-Informed Neural Networks with Physiologically-based Pharmacokinetic Modelling: A Novel Physics-based Framework for Parameter Discovery

Wednesday 10:30-12:00

I-056Vincent Chang

Subject-level meta-analysis of obeldesivir clinical safety and pharmacokinetic data

Wednesday 10:30-12:00

I-057Jonathan Chauvin

Automated concentration-QT data preparation, model selection and reporting in R

Wednesday 10:30-12:00

I-058Jun Chen

Population Pharmacokinetic and Pharmacodynamic Modeling and Simulations of Danicopan in Combination with Eculizumab/Ravulizumab for Patients with PNH Who Have Clinically Significant Extravascular Hemolysis (CS-EVH)

Wednesday 10:30-12:00

I-059Xiaomei Chen

Computer-intensive model-building explorations to facilitate understanding at the levels of methodology, implementation, and application

Wednesday 10:30-12:00

I-060Zhendong Chen

A joint pharmacometric model of iohexol and creatinine administered through a meat meal to assess GFR and renal OCT2/MATE activity

Wednesday 10:30-12:00

I-061Amy S. Y. Cheung

Cabotegravir Population Pharmacokinetic Analysis of Adult and Adolescents pooled population who are living with HIV or at risk for HIV and receiving HIV pre-exposure prophylaxis (PrEP)

Wednesday 10:30-12:00

I-062Yi-han Chien

Modelling framework to evaluate anti-viral PROTACs

Wednesday 10:30-12:00

I-063Sheng Yuan Chin

Use of physiologically-based pharmacokinetic modelling to assess the drug-disease interaction of caffeine in cancer subjects and the influence of cytokine-mediated CYP1A2 suppression

Wednesday 10:30-12:00

I-064Youjung Cho

Population pharmacokinetics of the antifungal immediate-release oral flucytosine to characterize absorption and food effects

Wednesday 10:30-12:00

I-065Seung Chan Choi

Demonstrating Similarity of Denosumab Biosimilar SB16 to Reference Denosumab Using Population PK-PD Modeling

Wednesday 10:30-12:00

I-066Wendy Chu

Pharmacokinetics of the antimalarial drug pyronaridine: impact of pregnancy, malaria infection and HIV co-infection

Wednesday 10:30-12:00

I-067Lorenzo Cifelli

PKPD modeling for rapid dose selection with IMPRES-M, a novel smoothing approach.

Wednesday 10:30-12:00

I-068Lindsay Clegg

A validated model of the neutralising antibody-efficacy relationship for monoclonal antibody pre-exposure prophylaxis against COVID-19

Wednesday 10:30-12:00

I-069Neva Coello

Enhancing Pharmacometric Analyses with Estimand Framework and Causal Inference

Wednesday 10:30-12:00

I-070Susan Cole

Optimisation and evaluation of a physiologically-based model for tacrolimus with mechanistic absorption to inform its use in pregnant and breastfeeding women

Wednesday 10:30-12:00

I-071Henrik Cordes

Towards pharmacokinetic profile prediction of sequence-based pharmaceuticals with machine learning

Wednesday 10:30-12:00

I-072Bárbara Costa

Drug-Drug Interaction of Lamotrigine and Efavirenz during Pregnancy

Wednesday 10:30-12:00

I-073James Craig

Multi-objective Optimization for Population Pharmacokinetic (PopPK) Model Selection Using NSGA-II and pyDarwin

Wednesday 10:30-12:00

I-074Sinziana Cristea

A semi-mechanistic approach to model simultaneously the ADC, total mAb and cytotoxic payload of sacituzumab tirumotecan

Wednesday 10:30-12:00

I-075Vincent Croixmarie

Comprehensive population PK/PD modeling of perindopril, indapamide, and bisoprolol in healthy volunteers: insights for fixed-dose combination therapy in hypertension

Wednesday 10:30-12:00

I-076Marina Cuquerella

Leveraging Two-Stage d Global Sensitivity Analysis method to inform parameter estimation in PBPK models

Wednesday 10:30-12:00

I-077Salvatore D'Agate

A model-based approach for the characterisation of anti-tubercular effects of BPaL combination therapy in an in vitro time-kill assay

Wednesday 10:30-12:00

I-078Harel Dahari

Beyond the RSE: Improving accuracy of in-host population modeling

Wednesday 10:30-12:00

I-079Huong Tra Dang

Physiological-based pharmacokinetics/pharmacodynamic modelling for Ivabradine and its major active metabolites, S18982

Wednesday 10:30-12:00

I-080Kseniia Danichkina

Survival data extraction: the comparison of methods, risk proportionality and informative censoring

Wednesday 10:30-12:00

I-081Anna Dari

Semi-mechanistic model of antitumor response after oncolytic virus administration

Wednesday 10:30-12:00

I-082Hippolyte Darre

A Physiologically Based Pharmacokinetic Model for Pemetrexed in Metastatic EGFR-Mutated NSCLC: Application and prospective validation in the context of FLAURA2 Phase III

Wednesday 10:30-12:00

I-083Casey Davis

The Regularized Horseshoe for Covariate Selection Improves Convenience and Predictive Performance in Population PK/PD Models

Wednesday 10:30-12:00

I-084Rik de Greef

Efficiency comparison of different exact gradient solutions in First Order conditional methods mixed effect Non Linear Regression

Wednesday 10:30-12:00

I-085Dr. Amparo de la Peña

Improvements in Data Quality Can Boost Efficiency and Reduce Development Costs: Findings from a Survey of Pharmacometric CROs

Wednesday 10:30-12:00

I-086AHM de Vries Schultink

Population pharmacokinetics of total and protein-unbound prednisolone in children with immune-mediated and inflammatory diseases

Wednesday 10:30-12:00

I-087Gerbert Coen De Waard

Unraveling the PK of target site cefuroxime exposure in prosthetic joint infection patients: a population PK analysis

Wednesday 10:30-12:00

I-088Wilbert De Witte

Continuous infusion simulations in PBPK and QSP models reveal steady-state properties and rate-limiting steps.

Wednesday 10:30-12:00

I-089Birses Debir

Application of Quantitative Systems Pharmacology (QSP) Approach to Guide Development of a Bispecific CD40-EpCAM Antibody, KK2269.

Wednesday 10:30-12:00

I-090Oscar Della Pasqua

Implications of credibility criteria for model-informed evidence for the evaluation and approval of medicinal products for rare/paediatric diseases: a case study on the use of chelation therapy in patients affected by transfusion dependent haemoglobinopathies.

Wednesday 10:30-12:00

I-091Marie-Laure Delporte

A pharmacokinetics–time to alleviation of symptoms model to support extrapolation of baloxavir marboxil efficacy in pediatric patients with influenza

Wednesday 10:30-12:00

I-092Cleo Demeester

Wednesday 10:30-12:00

I-093Abdallah Derbalah

Leveraging PBPK Modelling to Optimize Oligonucleotide Therapeutics: Sustained-Release Strategies for Enhanced Targeting Specificity

Wednesday 10:30-12:00

I-094LEKSHMI DHARMARAJAN

Model-informed scheduling of drug combinations for optimal treatment of cancer: a case study of JDQ443 and TNO155 dose regimen optimization

Wednesday 10:30-12:00

I-095ALESSANDRO Di Deo

Pharmacokinetics and dose optimisation of continuous fentanyl infusion in newborns with hypoxic–ischaemic encephalopathy undergoing therapeutic hypothermia

Wednesday 10:30-12:00

I-096Giovanni Di Veroli

A new model of Tumor Growth Inhibition for pseudo-progression in Immuno-Oncology

Wednesday 10:30-12:00

I-097Nada Dia

Optimizing vancomycin dosing in older patients: predictive performance of pharmacometrics models

Wednesday 10:30-12:00

I-098Ricardo Diaz De Leon Ortega

A PBPK based simulation study to predict potential gastric transit time and permeability driven drug – drug interactions caused by Rybelsus® (semaglutide + SNAC)

Wednesday 10:30-12:00

I-099Marco Dionisi

Credibility assessment of model informed drug development (MIDD) in pediatric pain: a review of pediatric investigation plans from 2008 to 2024

Wednesday 10:30-12:00

I-100Nassim DJEBLI

Population Pharmacokinetic modeling of Dexmedetomidine Nasal Spray in Chinese adults and children

Wednesday 10:30-12:00

I-101Happy Djokoto

Model Informed Assessment of QT prolongation during drug development: A Three-Year Retrospective Analysis of EMA Scientific Advices

Wednesday 10:30-12:00

I-102Laurence Dodd

Integration of a Novel First-Order Release Z-Factor Dissolution Model with Global Sensitivity Analysis to Guide Formulation Development using Physiologically-Based Biopharmaceutics in OSPSuite v12

Wednesday 10:30-12:00

I-103Stephen Duffull

Investigating survivorship bias in disease progression modelling for Duchenne muscular dystrophy

Wednesday 10:30-12:00

I-104Thomas Duflot

Population PK/PD modeling of levobupivacaine and ropivacaine for motor block in spinal anesthesia

Wednesday 10:30-12:00

I-105Salome Dumasdelage

Translational modeling of Tumor Growth Inhibition of an antibody-drug conjugate in Oncology

Wednesday 10:30-12:00

I-106Jacob Dumbleton

reportifyr: an R-based Open-Source Tool for Automated Reporting

Wednesday 10:30-12:00

I-107Khanh Linh Duong

Population Pharmacokinetic Model of Darunavir and Ritonavir in Pregnant and Postpartum Women with Human Immunodeficiency Virus Infection

Wednesday 10:30-12:00

I-108Raunak Dutta

Translational Modeling of ADC Efficacy and Hematological Toxicity: A QSP Approach for FIH Dose Recommendation with T-DM1 as an Exemplar

Wednesday 10:30-12:00

I-109Aspire Editor

Population Pharmacokinetic Analysis of Lenacapavir in People Who Want or Need Pre-Exposure Prophylaxis

Wednesday 10:30-12:00

I-110Mehdi El Hassani

Population pharmacokinetics with sparse data: To develop or evaluate? A case study with piperacillin in geriatric patients.

Wednesday 10:30-12:00

I-111Selma El Massaoudi

Evaluating the impact of treatment discontinuation on the outcome of clinical trials for weight management: A simulation study

Wednesday 10:30-12:00

I-112Jeroen Elassaiss-schaap

Extension of IMPRES-M, the smoothing impulse-response PK-PD framework, to population pharmacokinetic analysis

Wednesday 10:30-12:00

I-113Douglas Eleveld

OpenPMX software for FOCE-I estimation

Wednesday 10:30-12:00

I-114Ibrahim El-haffaf

Joint model for piperacillin and meropenem: assessing the impact of a joint pharmacokinetic modeling approach on covariate inclusion and probability of target attainment

Wednesday 10:30-12:00

I-115Loic Etheve

A Physiologically Based Pharmacokinetic Model for Osimertinib in Metastatic EGFR-Mutated NSCLC: Application and prospective validation in the context of FLAURA2 Phase III

Wednesday 10:30-12:00